Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.4.1: prohibited at all times. Non-Specified. [1]
S4.4.1 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Experimental evidence
A primary study investigated SR9011 metabolism in human liver microsomes alongside SR9009. Its verification of an internet-sold product concerned SR9009, not SR9011. The two compounds should not share an asserted consumer-product finding merely because they were studied together. [2]
- In-vitro study; no administered-human therapeutic benefit or safety was established.
What remains uncertain
- The foundational Nature paper could not be opened. Broader circadian and animal-benefit claims were omitted, and no exact SR9011 contamination pathway was established.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011 ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.